Nanordica Medical raises €1.6M to bring antibiotic-free chronic wound treatment to market

Overview

Estonian medtech company Nanordica Medical raised 1.6 million euros to bring Premotiv, an antibiotic-free dressing for chronic wounds, to the European market. The dressing uses copper and silver nanoparticles to fight infection and speed healing without antibiotics, and it targets hard-to-heal cases such as diabetic foot ulcers. The round was led by Estonian fund 2C Ventures, and the money funds a large clinical study and the safety certification needed to sell across Europe.

Key Takeaways

Nanordica Medical raised 1.6 million euros to commercialize Premotiv, a wound dressing that prevents infection without antibiotics, addressing the rise in antibiotic resistance.
The round was led by 2C Ventures, with Specialist VC, Superangel, Amalfi, the Health Founders syndicate, and the EstBAN syndicate also taking part.
In a 30-patient randomized trial published in the Journal of Wound Care, Premotiv shrank wound area by 43 percent in one week versus 13 percent for standard silver dressings.
The technology pairs copper with silver nanoparticles, a combination the founders found inactivates bacteria up to 8 times better than conventional antibacterial dressings while using about 40 times less silver.
The new money completes a larger trial of more than 120 diabetic foot ulcer patients and finalizes CE marking, the certification required to sell across Europe.
A veterinary version called Ravimus Vet launched in 2023 and now sells in six countries, giving the company early revenue before its human product reaches market.

Stats & Key Facts

#1.6 million euros raised in the funding round led by 2C Ventures.
#43 percent wound area reduction in one week with Premotiv, compared with 13 percent for standard silver dressings, in a 30-patient trial.
#More than 120 patients enrolled in the ongoing multicenter double-blind diabetic foot ulcer trial.
#2.4 million euro European Innovation Council Accelerator grant previously awarded to the company.
#Around 100 million people worldwide live with chronic wounds, a high-cost burden for health systems.
#Six countries where the veterinary product Ravimus Vet is sold since its 2023 launch.

Nanordica Medical raises 1.6 million euros to launch Premotiv in Europe

The Estonian medtech company secured fresh funding to move its lead product from clinical testing toward commercial sale.

Nanordica Medical, a medtech company based in Estonia, raised 1.6 million euros to bring its Premotiv wound dressing to the European market. The product treats chronic wounds without antibiotics, fighting infection while the wound heals.

The round was led by Estonian fund 2C Ventures. Specialist VC, Superangel, and Amalfi joined, along with the Health Founders syndicate led by Erki Molder and the EstBAN syndicate led by Heidi Kakko and Martin Gorosko. CEO and co-founder Olesja Bondarenko leads the company, which began in 2019 as a spin-off of Estonia's National Institute of Chemical Physics and Biophysics.

How copper and silver nanoparticles fight wound infection

The science behind Premotiv rests on a discovery about how two metals work together.

›The founders found that combining copper with silver nanoparticles inactivates bacteria up to 8 times better than conventional antibacterial solutions.
›The stronger effect lets the dressing work at low concentrations that stay safe for human skin cells.
›Nanordica's dressings hold on average about 40 times less silver than standard wound dressings used today.
›The approach prevents infection and supports wound closure at the same time, instead of forcing a tradeoff between killing bacteria and protecting skin.

Clinical trial data showing faster healing than silver dressings

Evidence from a published study sits at the center of the company's pitch to investors and regulators.

In a randomized controlled trial of 30 patients published in the Journal of Wound Care, Premotiv produced a 43 percent reduction in wound area after one week, compared with 13 percent for standard ionic silver dressings. The patients in the study had diabetic foot ulcers, one of the most stubborn types of chronic wound.

Nanordica is now running a larger multicenter, double-blind randomized trial in patients with diabetic foot ulcers, with more than 120 people already enrolled. Stronger trial results would support both regulatory approval and adoption by clinics.

What the funding pays for: a larger trial and CE marking

The capital is tied to two milestones the company needs before it can sell across Europe.

›Complete the larger multicenter trial in diabetic foot ulcer patients now underway.
›Finalize CE marking, the certification that allows commercial sale across the European market.
›Move Premotiv from research stage to a product that hospitals and clinics can order.

Grants, patents, and a veterinary product already earning revenue

The company carries outside validation and an early commercial track record.

Nanordica received a 2.4 million euro European Innovation Council Accelerator grant and a recently granted European patent covering its technology. Both signal that independent reviewers judged the science and business worth backing.

A veterinary version of the product, Ravimus Vet, launched in 2023 and now sells in six countries. That product gives the company early revenue and real-world use of its technology while the human dressing works through clinical study and certification.

Why antibiotic-free wound care matters now

The market context explains the investor interest in this approach.

Rising antibiotic resistance is pushing hospitals and researchers toward treatments that fight infection without relying on antibiotics. A dressing that controls bacteria through metal nanoparticles fits that need, since it does not add to the resistance problem the way repeated antibiotic use does.

Chronic wounds are a large and costly burden. Around 100 million people worldwide live with them, and they consume significant resources from health systems. Faster healing, as the trial data suggests, would lower costs and reduce serious outcomes such as amputation among diabetic patients.

Frequently Asked Questions

What is Premotiv and how does it heal wounds?

Premotiv is a wound dressing from Nanordica Medical that fights infection using copper and silver nanoparticles instead of antibiotics. The combination of the two metals controls bacteria while supporting wound closure, and it works at low concentrations that stay safe for skin cells.

How much did Nanordica Medical raise and who led the round?

The company raised 1.6 million euros. Estonian fund 2C Ventures led the round, with participation from Specialist VC, Superangel, Amalfi, the Health Founders syndicate, and the EstBAN syndicate.

What did the clinical trial show?

In a 30-patient randomized trial published in the Journal of Wound Care, Premotiv cut wound area by 43 percent after one week, compared with 13 percent for standard silver dressings, in patients with diabetic foot ulcers. A larger trial with more than 120 patients is now underway.

What will the company do with the money?

Nanordica will complete its larger multicenter clinical trial and finalize CE marking, the certification required to sell a medical device across Europe. Those two steps clear the path to commercial launch.

Does Nanordica already sell any products?

Yes. A veterinary version called Ravimus Vet launched in 2023 and sells in six countries, providing early revenue while the human dressing moves through trials and certification.

With fresh funding, published trial results, and a granted European patent, Nanordica Medical is positioning Premotiv to reach the European market as an antibiotic-free option for chronic wounds. The larger trial and CE marking now stand as the final hurdles before commercial launch.